Highlights Titan Pharmaceuticals, Inc.

Equities

TTNP

US8883147055

Market Closed - Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
6.9 ^USD	+1.17%		+0.29%	-16.36%

04-01	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-26	Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	01-26	MT
Reverse Split: 1 of 20	01-08	FA
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..	31/08/23	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. for $52 million.	26/07/23	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop	15/12/22	MT
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US	12/12/22	MT
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc	12/12/22	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant	05/07/22	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Activist Investing Acquires Minority Stake in Titan Pharmaceuticals	25/04/22	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/03/22	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Titan Pharmaceuticals, Inc. Reports Additional Positive Data from an Ongoing in Vivo Study of its Human Kappa-Opioid Receptor Agonist Proneura?-Based Implant in an Established 5'-Gnti Itch-Induced Mouse Model	08/11/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Titan Pharmaceuticals, Inc.

Equities

TTNP

US8883147055

Highlights

Filters